Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial.
about
De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinomaHPV Associated Head and Neck CancerHPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment StrategiesTargeted Therapy in Oropharyngeal Squamous Cell Carcinoma: The Implications of HPV for TherapyThe current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neckProtein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerHPV in oropharyngeal cancer: the basics to know in clinical practiceThe role of systemic treatment before, during, and after definitive treatmentHuman papilloma virus infection in head and neck cancerAn updated overview of HPV-associated head and neck carcinomasWhat is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinomaDistant metastasis in p16-positive oropharyngeal squamous cell carcinoma: a critical analysis of patterns and outcomesCurrent and future techniques for human papilloma virus (HPV) testing in oropharyngeal squamous cell carcinoma.Management of Oropharyngeal Cancer in the HPV Era.Clinical features and treatment strategy for HPV-related oropharyngeal cancer.Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis.Role of human papillomavirus in oropharyngeal squamous cell carcinoma: A review.Counseling the patient with potentially HPV-related newly diagnosed head and neck cancerClinical and scientific impact of human papillomavirus on head and neck cancer.Retrospective analysis of the impact of HPV status and smoking on mucositis in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemotherapy and radiotherapyPrognostic factors and survival unique to surgically treated p16+ oropharyngeal cancer.Human Papillomavirus-associated oropharyngeal cancer: an observational study of diagnosis, prevalence and prognosis in a UK populationSerum antibodies to the HPV16 proteome as biomarkers for head and neck cancerInfluence of smoking history on imaging characteristics among patients with human papillomavirus-positive oropharyngeal cancer: a blinded matched-pair analysisHelical tomotherapy in head and neck cancer: a European single-center experience.The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas.Emergence of HPV16-positive oropharyngeal cancer in Black patients over time: University of Maryland 1992-2007.Xenograft assessment of predictive biomarkers for standard head and neck cancer therapiesHPV-Positive Oropharyngeal Carcinoma: A Systematic Review of Treatment and Prognosis.A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.Oropharyngeal cancer as a driver of racial outcome disparities in squamous cell carcinoma of the head and neck: 10-year experience at the University of Maryland Greenebaum Cancer Center.HPV Serum Antibodies as Predictors of Survival and Disease Progression in Patients with HPV-Positive Squamous Cell Carcinoma of the Oropharynx.Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706).Deregulation of SYCP2 predicts early stage human papillomavirus-positive oropharyngeal carcinoma: A prospective whole transcriptome analysisChemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer.The rationale for HPV-related oropharyngeal cancer de-escalation treatment strategiesSurgical management of oropharyngeal squamous cell carcinoma: Survival and functional outcomes.Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer.Future directions in research, treatment and prevention of HPV-related squamous cell carcinoma of the head and neck.
P2860
Q24200362-C3714C50-2FA5-4F37-9C9B-AF598D39DDBBQ26741386-AD76255C-E685-4B8F-B36A-A2B05CE34C45Q26752584-C9EFB5D0-5A75-4786-B8A7-3E23219808C1Q26824925-4A2A1EBB-89FE-47CA-BE5A-A7E1A9767E27Q26830495-A79C9614-FF67-4D23-816C-62039276B4BBQ26852215-47B7D99E-C4EE-4EF8-B9D4-21CCFC26AB4CQ26853669-E8560CAB-2B1A-4508-B55C-026C4C1CF32EQ26859285-BB5D4114-6269-4674-931A-EA4C554A04CFQ26996504-AF2167DC-A46D-488B-9078-71690A8B85CFQ27014019-E4649E14-4B3F-40B1-9C9F-177CE7C9EE98Q27026269-8A43BD96-AE50-46CF-8D2F-C583D4455E24Q27853077-332DFF5E-1A86-456C-ABBF-DDDC47DB7673Q28301587-DA82B04A-96B2-4371-8AD9-2F8D1533F634Q30235327-CF473F0B-47AE-47B7-90BC-680B43BF29A6Q30248326-23967004-97E3-4381-88F9-952C987A3E04Q30249150-577CF3C0-0298-48B0-A9EA-E903BAC4A68DQ30650708-B04BC4A1-10E5-43A4-B0B1-AD01E2F17A98Q33770030-589A0E2B-B0AF-4B39-BCD7-2ABFEC47AC4DQ33908473-C49F3E5D-027B-4A00-93DD-EE68678B9525Q34031281-94ADB435-651F-44A5-9F3E-CD995B6D5DF1Q34106680-0D239EEA-44D0-43AA-80B7-A4F535E10E43Q34394972-C7740D58-728A-4665-B774-3CCAF7790B23Q34698871-1B5815AE-C9D5-4065-A536-C0177727DD24Q35034741-7F2F1087-814D-431E-ACE5-F22A00051686Q35053722-DEE70A72-60F8-4427-830A-B88B02A6E53CQ35151101-8E0E78C6-20E6-43A6-BD51-6BAA2260DEF2Q35344832-3C6924E3-0898-4F4C-AA46-3264A42FEC3FQ35599106-3618108C-34F5-4C95-9450-24320EAD4529Q35602135-974465ED-1D83-4B2A-9E68-7D6AA8F8C5C8Q35678211-26EAB213-737A-4756-BAF0-A716B39EC927Q35693308-392A5320-9CE1-410B-AE8A-8EDF202A83ECQ35706839-F881F43A-DE18-44FE-89A7-E2D3A78B99A1Q35750840-715AC90C-D82E-47A3-9F2F-1B93A2BF5D68Q35754239-28112E62-FC46-47B4-A6E4-C491D1F7AD4BQ35763033-B8061E17-ADED-4DEE-AF36-F2583F614598Q35837683-63B351A1-5B9E-43AC-86C6-DD3E561B6EAEQ35838231-DD919219-2D96-43CC-BE06-3BD770A8788CQ35875691-3F65538C-5531-4B29-9242-D5A5515965F2Q36074308-79AF8074-7F11-498D-95B1-5A00DDFD679AQ36088069-89B0097D-D7D5-4E3C-8E49-8288B944D462
P2860
Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Survival and human papillomavi ...... international phase III trial.
@ast
Survival and human papillomavi ...... international phase III trial.
@en
type
label
Survival and human papillomavi ...... international phase III trial.
@ast
Survival and human papillomavi ...... international phase III trial.
@en
prefLabel
Survival and human papillomavi ...... international phase III trial.
@ast
Survival and human papillomavi ...... international phase III trial.
@en
P2093
P2860
P356
P1433
P1476
Survival and human papillomavi ...... international phase III trial
@en
P2093
K J Cullen
M R Posner
N J Sarlis
O Goloubeva
R I Haddad
P2860
P304
P356
10.1093/ANNONC/MDR006
P577
2011-02-11T00:00:00Z